AUTHOR=Snowdin Jacob W. , Mercuro Nicholas J. , Madaio Michael P. , Rawlings Stephen A. 

TITLE=Case report: Successful treatment of OXA-23 Acinetobacter baumannii neurosurgical infection and meningitis with sulbactam-durlobactam combination therapy

JOURNAL=Frontiers in Medicine

VOLUME=11

YEAR=2024

URL=https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2024.1381123

DOI=10.3389/fmed.2024.1381123

ISSN=2296-858X

ABSTRACT=<p>Meningitis caused by <italic>Acinetobacter</italic> species is a rare complication of neurosurgical procedures, although it is associated with high morbidity and mortality. Carbapenem-resistant <italic>Acinetobacter</italic> is particularly difficult to treat, considering the limited selection and tolerability of effective antimicrobials. Sulbactam-durlobactam was approved by the FDA in 2023 for treatment of hospital-acquired and ventilator-associated pneumonia due to susceptible strains of <italic>Acinetobacter</italic>, including carbapenem-resistant <italic>Acinetobacter baumannii</italic>. Here, we present a case of carbapenem-resistant <italic>Acinetobacter baumannii</italic> neurosurgical infection and meningitis successfully treated with sulbactam-durlobactam combination therapy.</p>